OBJECTIVE: To determine whether maternally derived antibodies interfere with the mucosal immune response following intranasal (IN) vaccination of newborn calves with a multivalent modified-live virus vaccine. DESIGN: Randomized controlled clinical trial. ANIMALS: 23 newborn Holstein bull calves. PROCEDURES: Calves received colostrum and were assigned to group A (unvaccinated control calves), group B (IN vaccination on day 0), or group C (IN vaccination on days 0 and 35). Serum and nasal secretion sample (NSS) titers of antibodies specific for bovine herpesvirus 1, bovine viral diarrhea virus 1, and bovine viral diarrhea virus 2; WBC counts; and NSS interferon concentrations were determined up to day 77. RESULTS: Calves had high serum titers of maternally derived antibodies specific for vaccine virus antigens on day 0. High IgA and low IgG titers were detected in NSSs on day 0; NSS titers of IgA decreased by day 5. Group B and C NSS IgA titers were significantly higher than those of group A on days 10 through 35; group C IgA titers increased after the second vaccination. Serum antibody titers decreased at a similar rate among groups of calves. Interferons were not detected in NSSs, and calves did not develop leukopenia. CONCLUSIONS AND CLINICAL RELEVANCE: IN vaccination of newborn calves with high concentrations of virus-neutralizing antibodies increased NSS IgA titers but did not change serum antibody titers. Revaccination of group C calves on day 35 induced IgA production. Intranasal vaccination with a modified-live virus vaccine was effective in calves that had maternally derived antibodies.
OBJECTIVE: To determine whether maternally derived antibodies interfere with the mucosal immune response following intranasal (IN) vaccination of newborn calves with a multivalent modified-live virus vaccine. DESIGN: Randomized controlled clinical trial. ANIMALS: 23 newborn Holstein bull calves. PROCEDURES: Calves received colostrum and were assigned to group A (unvaccinated control calves), group B (IN vaccination on day 0), or group C (IN vaccination on days 0 and 35). Serum and nasal secretion sample (NSS) titers of antibodies specific for bovine herpesvirus 1, bovine viral diarrhea virus 1, and bovine viral diarrhea virus 2; WBC counts; and NSS interferon concentrations were determined up to day 77. RESULTS:Calves had high serum titers of maternally derived antibodies specific for vaccine virus antigens on day 0. High IgA and low IgG titers were detected in NSSs on day 0; NSS titers of IgA decreased by day 5. Group B and C NSS IgA titers were significantly higher than those of group A on days 10 through 35; group C IgA titers increased after the second vaccination. Serum antibody titers decreased at a similar rate among groups of calves. Interferons were not detected in NSSs, and calves did not develop leukopenia. CONCLUSIONS AND CLINICAL RELEVANCE: IN vaccination of newborn calves with high concentrations of virus-neutralizing antibodies increased NSS IgA titers but did not change serum antibody titers. Revaccination of group C calves on day 35 induced IgA production. Intranasal vaccination with a modified-live virus vaccine was effective in calves that had maternally derived antibodies.
Authors: Nathan E N Erickson; Adam Berenik; Herbert Lardner; Stacey Lacoste; John Campbell; Sheryl Gow; Cheryl Waldner; John Ellis Journal: Can Vet J Date: 2021-01 Impact factor: 1.008